Aids vaccine Enters Phase 2 Trial

Volunteers enroll for second-step vaccine trial
by Tamar Kahn, Science and Health Editor
BUSINESS DAY

CAPE TOWN - Scientists yesterday began enrolling
volunteers for SA's first phase two clinical trial of a
candidate HIV vaccine, under a multisite study funded
by the International AIDS Vaccine Initiative.

Scientists will be testing a vaccine called tgAAC09,
developed by Nasdaq-listed Targeted Genetics
Corporation, which combines two of the latest
techniques for helping the body defend itself
against HIV.

More than 6-million South Africans are infected with HIV.
With no cure in sight, a vaccine offers the best hope of
combating the pandemic.

For more the full story click here

Positive News hopes this vaccine proves to be successful
and we can begin to turn the tide on this dreadful
destructive disease.